The last day was jammed with important reports and research including the late breaking abstracts.
What imaging modality is best in GCA?
Dutch study: n=42
?GCA got all three of USS, PET/CT, MRI
Overall performance basically the same between all three.
Important details in 🧵
but reasonable to say you can be happy with whatever you’ve got!
— David Liew (@drdavidliew) November 13, 2022
HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!
Stop RA: RCT HCQ vs. PBO in pts at-risk
Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%
Trial interrupted as met futility criteria.https://t.co/n31OmsjLhM
— Aurelie Najm (@AurelieRheumo) November 13, 2022
Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
363 pt P2, double-blind PBO-controlled 48 wk study
DEUC 3 mg BID, 6 BID, 12 QB vs PBO:
At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk.
AEs: similar bw PBO and DEUC. No VTE@RheumNow #ACRBest pic.twitter.com/uamJe05odq
— Eric Dein (@ericdeinmd) November 13, 2022
Are your SpA pts planning on conceiving? Be careful with NSAID use
French study found age and NSAID use associated with longer time-to-conception.
Factors not associated: smoking, BASDAI score, DMARD use#ACRBest Abs#1673 @RheumNow #ACR22 pic.twitter.com/D63XTY7IB8
— Robert B Chao, MD (@doctorRBC) November 14, 2022
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow pic.twitter.com/wNAzTaLhsM
— Janet Pope (@Janetbirdope) November 14, 2022
#ACR22 Abstr#2061 It’s time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest pic.twitter.com/swYn2g4hqe
— Md Yuzaiful Md Yusof (@Yuz6Yusof) November 14, 2022
Which patients with IIM are high risk for #cancer?
📍Age > 40y at dz onset
📍Persistent high dz despite immunosuppressive tx
— Catherine Sims, MD (@DrCassySims) November 14, 2022
Very cool preclinical plenary @MaxKonigMD
Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells)
— Mike Putman (@EBRheum) November 14, 2022